Edition:
United States

T2 Biosystems Inc (TTOO.OQ)

TTOO.OQ on NASDAQ Stock Exchange Global Market

5.54USD
27 Mar 2017
Change (% chg)

$0.26 (+4.92%)
Prev Close
$5.28
Open
$5.23
Day's High
$5.64
Day's Low
$5.23
Volume
11,852
Avg. Vol
19,079
52-wk High
$11.22
52-wk Low
$4.89

Latest Key Developments (Source: Significant Developments)

T2 Biosystems files for resale of up to 6.06 mln shares by selling stockholder
Monday, 20 Mar 2017 04:08pm EDT 

T2 Biosystems Inc :T2 biosystems inc - files for resale of up to 6.06 million shares of co's common stock, par value $0.001 per share, by selling stockholder.  Full Article

T2 Biosystems qtrly loss per share $0.48
Wednesday, 8 Mar 2017 04:57pm EST 

T2 Biosystems Inc : Qtrly loss per share $0.48 . T2 Biosystems Inc - on March 2, Shawn Lynch notified company of his resignation from his position as company's CFO effective immediately . T2 Biosystems Inc - Lynch indicated that he resigned for personal reasons .Qtrly total revenue $910,000 versus $1 million.  Full Article

T2 Biosystems reports Q4 revenue $910,000
Monday, 13 Feb 2017 04:01pm EST 

T2 Biosystems Inc : T2 Biosystems reports fourth quarter and full-year 2016 results . Q4 revenue $910,000 . Q4 revenue view $1.4 million -- Thomson Reuters I/B/E/S .T2 Biosystems - sees higher product revenue in Q1 2017 from an increase in T2Candida panel sales due to increased patient testing across installed base.  Full Article

T2 Biosystems says reports preliminary Q4 results
Monday, 9 Jan 2017 06:30am EST 

T2 Biosystems Inc : T2 biosystems reports preliminary fourth quarter results and operational progress . T2 biosystems reports preliminary fourth quarter results and operational progress .Sees estimated preliminary product revenue indicates year-over-year growth by over 50 percent compared to 2015 q4.  Full Article

Japan's Canon Inc reports 19.9 pct stake in T2 Biosystems - SEC filing
Friday, 30 Sep 2016 06:29am EDT 

T2 Biosystems Inc : Japan's Canon Inc reports 19.9 pct stake in T2 Biosystems Inc as of September 21, 2016 - SEC filing . Canon says T2 Biosystems and Canon USA entered into a voting and standstill agreement and a registration rights agreement . Canon says T2 Biosystems has agreed to give Canon USA certain board designation rights . Canon says T2 Biosystems to initially appoint Seymour Liebman, an EVP at Canon USA, as a class I director on the T2 board .Canon says Canon USA beneficially owns 6 million shares of common stock of T2 Biosystems as of Sept 21.  Full Article

T2 biosystems says it has sold $39.7 million in equity financing
Tuesday, 27 Sep 2016 04:51pm EDT 

T2 Biosystems Inc :Says it has sold $39.7 million in equity financing - SEC filing.  Full Article

Canon U.S.A. announces equity investment in T2 Biosystems
Thursday, 22 Sep 2016 09:26am EDT 

Canon U.S.A. <7751.T> : Canon U.S.A. announces equity investment in T2 Biosystems Inc . Has purchased approximately $40 million of T2 biosystems stock at closing market price of $6.56 in a private placement . Says investment results in Canon's ownership of approximately 19.9 percent of T2 Biosystems .Seymour Liebman , EVP, chief administrative officer and general counsel, Canon U.S.A Inc will join T2 Biosystems board of directors.  Full Article

T2 Biosystems reports Q2 loss per share $0.58
Monday, 1 Aug 2016 04:00pm EDT 

T2 Biosystems Inc : T2 Biosystems reports 2016 second quarter, six month results . Q2 loss per share $0.58 . Q2 revenue $990,000 . Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Q2 revenue view $1.5 million -- Thomson Reuters I/B/E/S . T2 Biosystems Inc says continues to target closing a total of 45 hospital commitments globally during 2016 . T2 Biosystems Inc says research revenue is expected to be comparable to what was realized in Q2 of 2016 . Q3 earnings per share view $-0.54, revenue view $2.2 million -- Thomson Reuters I/B/E/S . T2 Biosystems Inc says anticipates higher product revenue in Q3 of 2016 than was realized in first and second quarters of 2016 .T2 Biosystems Inc sees total Q3 of 2016 operating expenses to be between $12.3 million and $12.8 million.  Full Article

T2 Biosystems Announces Closing of Public Offering of Common Stock
Wednesday, 9 Dec 2015 12:00pm EST 

T2 Biosystems, Inc:Says closing of its underwritten public offering of 3,500,000 shares of common stock at a public offering price of $9.75 per share, before underwriting discounts, for gross proceeds of $34,125,000.In addition, T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock at the public offering price, less the underwriting discount.All of the shares of the common stock sold in the offering were offered by T2 Biosystems.Goldman, Sachs & Co. acted as the book-running manager for the offering.Additional underwriters included Leerink Partners LLC, Canaccord Genuity Inc. and Cantor Fitzgerald & Co.  Full Article

T2 Biosystems Announces Pricing of Public Offering of Common Stock
Thursday, 3 Dec 2015 08:13pm EST 

T2 Biosystems, Inc:Says pricing of its underwritten public offering of 3,500,000 shares of common stock at a public offering price of $9.75 per share, before underwriting discounts, for gross proceeds of $34,125,000.In addition, T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock at the public offering price, less the underwriting discount.All of the shares of the common stock to be sold in the offering will be offered by T2 Biosystems.offering is expected to close on or about December 9, 2015, subject to customary closing conditions.Goldman, Sachs & Co. is acting as the book-running manager for the offering.Additional underwriters include Leerink Partners LLC, Canaccord Genuity Inc. and Cantor Fitzgerald & Co.  Full Article

More From Around the Web

BRIEF-T2 Biosystems files for resale of up to 6.06 mln shares by selling stockholder

* T2 biosystems inc - files for resale of up to 6.06 million shares of co's common stock, par value $0.001 per share, by selling stockholder Source text for Eikon: (http://bit.ly/2mmhevq) Further company coverage: